17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Inclusion Criteria:
Exclusion Criteria:
Capital Federal, C1181ACH, Argentina
Ciudad AutOnoma de Buenos Aire, 1118, Argentina
Ciudad Autonoma de Bueno, C1056ABJ, Argentina
Derqui Pilar, B1629AHJ, Argentina
Rio Patras, 26504, Greece
Guhawati, 781006, India
Rozzano MI, 20089, Italy
San Giovanni Rotondo FG, 71013, Italy
Cuernavaca Morelos, 62170, Mexico
Yongsan-Ku Seoul, South Korea
Sabadell Barcelona, 08208, Spain